What is CoolSculpting?
CoolSculpting operates at the intersection of medical technology and consumer wellness, specializing in non-invasive body contouring. The company utilizes advanced cryolipolysis—a process of controlled cooling—to selectively target and eliminate subcutaneous fat cells without the need for surgical intervention. Since its inception in 2009, the firm has carved out a distinct market position by providing a safe, effective alternative to traditional liposuction, thereby capturing significant share in the elective aesthetic procedure market. Its business model relies on the widespread adoption of its proprietary hardware by dermatologists and plastic surgeons, creating a recurring revenue stream through consumable components and clinical training programs.
How much funding has CoolSculpting raised?
CoolSculpting has raised a total of $136.3M across 3 funding rounds:
Series B
$20.3M
Series D
$25M
Stock Offering
$91M
Series B (2009): $20.3M with participation from Frazier Healthcare Ventures and Advanced Technology Ventures
Series D (2010): $25M led by Frazier Healthcare Ventures, Advanced Technology Ventures, and Venrock
Stock Issuance/Offering (2011): $91M, investors not publicly disclosed
Key Investors in CoolSculpting
Frazier Healthcare Ventures
A prominent investment firm focused on the biopharmaceutical and healthcare sectors, providing strategic capital to companies developing innovative medical treatments.
Advanced Technology Ventures
A bi-coastal venture capital firm with extensive experience in building market-leading enterprises across the healthcare, software, and IT infrastructure sectors.
Venrock
A historic venture capital firm known for partnering with founders to scale high-growth technology and healthcare companies through deep industry expertise.
What's next for CoolSculpting?
With the recent infusion of capital, CoolSculpting is well-positioned to accelerate its research and development pipeline and expand its clinical footprint. The strategic focus will likely shift toward enhancing the efficacy of its existing treatment protocols and exploring new applications for its cooling technology. As the company matures, management is expected to prioritize operational efficiency and market penetration, leveraging its strong balance sheet to defend its competitive moat against emerging aesthetic technologies. The continued support from seasoned venture capital partners provides the necessary institutional guidance to navigate the complexities of the medical device regulatory landscape while scaling commercial operations globally.
See full CoolSculpting company page
